Compare · AMGN vs OKYO
AMGN vs OKYO
Side-by-side comparison of Amgen Inc. (AMGN) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $239.09B, about 2920.4x OKYO ($81.9M).
- AMGN has been more active in the news (18 items in the past 4 weeks vs 8 for OKYO).
- AMGN has more recent analyst coverage (25 ratings vs 2 for OKYO).
- Company
- Amgen Inc.
- OKYO Pharma Limited
- Price
- $442.23-0.36%
- $1.60+5.26%
- Market cap
- $239.09B
- $81.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2022
- News (4w)
- 18
- 8
- Recent ratings
- 25
- 2
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest AMGN
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
- Oppenheimer reiterated coverage on Amgen with a new price target
- Morgan Stanley reiterated coverage on Amgen with a new price target
Latest OKYO
- Amendment: SEC Form 20-F/A filed by OKYO Pharma Limited
- Amendment: CHIEF DEVELOPMENT OFFICER Jacob Gary S bought $4,900 worth of shares (3,500 units at $1.40), increasing direct ownership by 3% to 112,420 units (SEC Form 4)
- Amendment: CHIEF EXECUTIVE OFFICER Dempsey Robert John bought $23,085 worth of shares (15,000 units at $1.54) (SEC Form 4)
- Amendment: Director Brancaccio John P bought $7,385 worth of shares (5,000 units at $1.48), increasing direct ownership by 17% to 35,201 units (SEC Form 4)
- Amendment: Chief Scientific Officer Patil Rajkumar V. bought $5,011 worth of shares (3,363 units at $1.49), increasing direct ownership by 20% to 20,030 units (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $35,000 worth of shares (25,000 units at $1.40) (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $32,625 worth of shares (22,500 units at $1.45) (SEC Form 4)
- Amendment: CHIEF MEDICAL OFFICER Mantelli Flavio bought $28,000 worth of shares (20,000 units at $1.40) (SEC Form 4)
- Chief Scientific Officer Patil Rajkumar V. was granted 3,363 shares, increasing direct ownership by 20% to 20,030 units (SEC Form 4)
- New insider Patil Rajkumar V. claimed ownership of 16,667 shares (SEC Form 3)